Bio

GRI Bio (NASDAQ:GRI) has received notice on July 2, 2024, from The Nasdaq that the Co. regained compliance with all applicable Nasdaq listing standards for continued listing on the Nasdaq. “We are very excited about this development and look forward to focusing our efforts on our core business-developing novel product candidatesContinue Reading

Biopharmaceutical company Innovent Biologics (OTCPK:IVBIY) and IASO Biotechnology enter agreement under which IASO will purchase Innovent’s (OTCPK:IVBIY) relevant rights of FUCASO under the original “BCMA CAR-T Cell Therapy Cooperation Agreement” at the agreed price and Innovent (OTCPK:IVBIY) will use the proceeds to acquire an 18% stake in IASO Bio. UnderContinue Reading

Md Majhrarul Alam Biotechnology company Tourmaline Bio (NASDAQ:TRML) said on Thursday that Ryan Robinson has been promoted to the post of CFO and treasurer, effective June 25. TRML shares were trading -2.49% pre-market. Robinson most recently served as vice president, finance and controller, at the company, in addition to holding the post of interimContinue Reading

NISIT RAWO 2seventy bio (NASDAQ:TSVT) traded higher premarket Thursday after announcing the completion of an asset purchase agreement under which Novo Nordisk (NVO) (OTCPK:NONOF) has acquired its Hemophilia A program and rights to certain other assets. The staff members working in the program will also join the pharma giant asContinue Reading

georgeclerk Oppenheimer has initiated Gossamer Bio at outperform expressing optimism on seralutinib, its inhaled tyrosine kinase inhibitor for pulmonary arterial hypertension (PAH). The firm has a $9 price target (~984% upside based on June 24 close). Analyst Andreas Argyrides said that the candidate’s safety and efficacy profile makes it “aContinue Reading